Skip to main content
. 2020 May 28;18:214. doi: 10.1186/s12967-020-02370-4

Table 6.

Secondary analysis 4: safety and tolerability of neo-adjuvant rituximab

Severity/grade Adverse events (n) Possible, probable, or definite attribution (n) Description of related adverse events (n of patients affected)
Mild/1 6 2 Fatigue (×2)
Moderate/2 3 2 Infusion related reaction (×2)
Severe/3 0 0
Life-threatening/4 1 0
Fatal/5 0 0
Total 10 4

Adverse events (description, timing, grade [CTCAE v4.03], severity, seriousness, and relatedness)